Is AOD-9604 Legal in Virginia? How to Access It Legally

What AOD-9604 Is and Why Its Legal Status Is Complicated

AOD-9604 is a synthetic fragment of human growth hormone (hGH), spanning amino acids 176 to 191 of the hGH C-terminus. Researchers initially studied it as an anti-obesity agent because it appeared to stimulate lipolysis without the insulin-desensitizing effects of full-length hGH. It is not approved by the FDA for any clinical indication.

The Compound's Origins and Mechanism

The peptide was originally developed by Metabolic Pharmaceuticals (Melbourne, Australia) and advanced to Phase IIb trials in obese adults during the early 2000s. A randomized, placebo-controlled Phase II study published in the peer-reviewed literature showed modest weight-loss effects at doses of 1 mg orally per day over 12 weeks, but the program did not advance to Phase III [1]. That gap between Phase II and Phase III data is a central reason regulators have not granted marketing approval.

At the molecular level, AOD-9604 may act on beta-3 adrenergic receptors in adipose tissue, promoting fat oxidation without stimulating IGF-1 production. Because it does not measurably raise IGF-1, researchers initially hypothesized it would carry a lower cancer-promotion risk than full-length hGH. That hypothesis has not been confirmed in large prospective studies [2].

Why "Not Approved" Does Not Mean "Illegal to Prescribe"

The FDA's approval authority covers finished pharmaceutical products sold in interstate commerce. A licensed physician may legally prescribe unapproved compounds for off-label or investigational purposes when those compounds are prepared by a licensed compounding pharmacy operating under 21 U.S.C. § 503A or § 503B [3]. The legality question therefore splits into two separate tracks: federal compounding rules and Virginia state pharmacy regulations.

Federal Regulatory Framework: The 503A/503B Compounding System

The Drug Quality and Security Act (DQSA) of 2013 created two categories of compounding pharmacies under FDA oversight. Section 503A governs traditional compounding pharmacies that prepare drugs for individual patients based on a valid prescription. Section 503B governs outsourcing facilities that may compound without patient-specific prescriptions but face stricter FDA inspection requirements [3].

The FDA Bulk Substances List and AOD-9604

This is where AOD-9604's status becomes specific. The FDA maintains a list of bulk drug substances that 503A pharmacies may use in compounding. In 2015, the agency evaluated AOD-9604 and declined to place it on the affirmative "Category 1" list (substances that may be compounded). Instead, the FDA placed it on "Category 2," meaning the substance is under evaluation and its use in compounding remains contested [4].

The practical effect is that a 503A pharmacy using AOD-9604 as a bulk substance operates in a regulatory gray area. The FDA has not issued an outright enforcement ban specifically targeting AOD-9604 compounding as of mid-2025, but the agency has broad authority to act against pharmacies using bulk substances not on the approved list. That enforcement risk is real, and it varies by FDA district office priorities.

503B outsourcing facilities face an even stricter standard. They may only compound using bulk substances the FDA has affirmatively nominated and approved for the outsourcing-facility list. AOD-9604 does not appear on that affirmative list [4].

GHRPs, GHRHs, and the Broader Peptide Crackdown

The FDA's 2022 and 2023 guidance documents restricting certain growth hormone secretagogues (such as ipamorelin, CJC-1295, and sermorelin) from compounding created confusion about whether AOD-9604 falls under the same enforcement umbrella [5]. It does not share the same receptor mechanism as those secretagogues, but the broader regulatory climate for peptides has tightened. Prescribers and pharmacies operating in this space should review current FDA guidance before initiating therapy.

Virginia State Law: What the Commonwealth Adds (and Doesn't)

Virginia does not have a state statute that specifically names AOD-9604. The Commonwealth regulates compounding through the Virginia Board of Pharmacy (Title 54.1, Chapter 33 of the Code of Virginia), which requires all compounding pharmacies to comply with USP Chapter <795> (non-sterile) or <797> (sterile) standards and to operate within federal law [6].

Virginia Board of Pharmacy Standards

The Virginia Board of Pharmacy does not maintain a separate state-level bulk substances list. Instead, it defers to FDA determinations. A Virginia-licensed pharmacy that compounds AOD-9604 is therefore subject to the same federal uncertainty described above. If the FDA were to take formal enforcement action against AOD-9604 compounding nationwide, Virginia pharmacies would be bound by that action.

Sterile peptide preparations (such as subcutaneous injection formulations) must meet USP <797> standards, which include strict beyond-use dating, environmental monitoring, and personnel training requirements [7]. Patients receiving injectable AOD-9604 should confirm their pharmacy holds a valid Virginia sterile compounding permit.

Virginia Medical Practice Act and Prescriber Obligations

Under the Virginia Medical Practice Act (Code of Virginia § 54.1-2900 et seq.), licensed physicians, nurse practitioners, and physician assistants with prescriptive authority may prescribe compounded preparations for individual patients when there is a legitimate medical purpose and a valid patient-provider relationship [6]. The prescriber must document clinical justification in the medical record. Prescribing AOD-9604 without a documented clinical rationale or without conducting an appropriate evaluation would expose the provider to Board of Medicine scrutiny.

Telehealth Access Under Virginia Law

Virginia's SB 1222 (2020) and subsequent amendments permit telehealth prescribing when the provider establishes an appropriate clinical relationship with the patient, which may include a synchronous audio-video visit. This means a Virginia patient may consult a licensed Virginia provider via telehealth and, if clinically appropriate, receive a prescription for compounded AOD-9604 sent to a Virginia-registered compounding pharmacy. The provider still must satisfy all prescribing and documentation obligations.

Clinical Evidence: What the Trials Actually Show

Honest discussion of legality requires honesty about the evidence base. Patients and prescribers should not conflate "accessible" with "proven effective."

Phase II Human Data

Metabolic Pharmaceuticals conducted a 12-week, randomized, double-blind, placebo-controlled Phase IIb trial in adults with obesity. The trial tested oral AOD-9604 at doses ranging from 0.25 mg to 9 mg per day. At the 1 mg dose, subjects lost a mean of approximately 2.8 kg versus 0.8 kg in the placebo group over 12 weeks, a difference that reached statistical significance [1]. The compound did not advance past this stage; a Phase III confirmatory trial was never completed.

No published Phase III randomized controlled trial has evaluated subcutaneous AOD-9604 for weight loss, body composition, or any other endpoint in humans. The subcutaneous route used in current compounding practice is therefore not supported by the same trial data that motivated earlier oral-dose research.

Animal and In Vitro Data

Several preclinical studies published in peer-reviewed journals confirm the lipolytic mechanism in rodent models. A study in the International Journal of Obesity demonstrated that AOD-9604 administered to obese Zucker rats reduced fat mass without measurable effects on blood glucose or IGF-1 [2]. Translating rodent lipolysis data to human clinical outcomes requires caution; many compounds that performed well in rodent obesity models have failed in human trials [8].

Safety Profile

AOD-9604 showed an acceptable safety profile in Phase II trials, with no serious adverse events attributed to the drug at doses up to 9 mg/day orally. Injection-site reactions are reported anecdotally with subcutaneous use. Long-term safety data beyond 12 weeks do not exist in published human studies. The FDA has not concluded that the compound is safe for human compounding use, which is part of why it remains on Category 2 rather than Category 1.

How Virginia Patients Can Access AOD-9604 Legally

The pathway is narrow but navigable. It requires a licensed provider, a valid clinical reason, and a compliant compounding pharmacy.

Step 1: Establish Care with a Licensed Virginia Provider

The patient must have a documented clinical relationship with a Virginia-licensed physician, NP, or PA who holds prescriptive authority. That relationship requires at minimum a thorough history, review of relevant labs (such as metabolic panel, lipid panel, and body composition assessment), and documented discussion of treatment alternatives including FDA-approved options such as semaglutide 2.4 mg (Wegovy) or tirzepatide 15 mg (Zepbound) for weight management [9].

The provider must document why AOD-9604 is being considered for this specific patient and what clinical outcome is being targeted. A prescription written without that documentation fails to meet the standard for legitimate medical purpose under Virginia law.

Step 2: Confirm Pharmacy Licensure and Compliance

The prescribing provider or patient should verify that the compounding pharmacy:

• Holds a current Virginia Board of Pharmacy compounding permit (or is registered as an out-of-state pharmacy shipping into Virginia)
• Operates under 503A (patient-specific prescriptions) rather than relying on 503B bulk compounding of AOD-9604
• Follows USP <797> standards for sterile injectable preparations
• Can provide a certificate of analysis (COA) from an accredited third-party laboratory confirming peptide identity, purity, and potency [7]

Patients should ask to see the COA before accepting any compounded peptide product. Potency and sterility failures in compounded injectables are a documented patient-safety risk, as the FDA's MedWatch database records [10].

Step 3: Understand What "Legal Access" Does Not Guarantee

Accessing AOD-9604 through a licensed provider and a compliant pharmacy is the most defensible legal path available in Virginia today. That path does not guarantee the FDA will not take future enforcement action against compounding of this substance. The Category 2 designation means the agency has not resolved the question. Patients and providers should monitor FDA guidance updates from the Center for Drug Evaluation and Research (CDER) compounding program [4].

"Compounded drugs are not FDA-approved," states the FDA's own guidance on 503A compounding, "which means FDA has not verified their safety, effectiveness, or quality." [3] That statement applies directly to compounded AOD-9604.

Comparing AOD-9604 to FDA-Approved Alternatives for Weight Management

Virginia patients who are interested in AOD-9604 for body-fat reduction should understand where it sits relative to approved options.

| Agent | FDA Approval | Mean Weight Loss (RCT) | Route | |---|---|---|---| | Semaglutide 2.4 mg (Wegovy) | Yes (2021) | 14.9% at 68 weeks (STEP-1, N=1,961) [9] | Subcutaneous weekly | | Tirzepatide 15 mg (Zepbound) | Yes (2023) | 20.9% at 72 weeks (SURMOUNT-1, N=2,539) [11] | Subcutaneous weekly | | AOD-9604 1 mg oral | No | ~2.8 kg at 12 weeks (Phase IIb, N=300 approx.) [1] | Oral (not currently compounded) |

The weight-loss magnitude from the single Phase IIb AOD-9604 trial is substantially smaller than what STEP-1 (semaglutide) and SURMOUNT-1 (tirzepatide) demonstrated in larger, longer trials. A clinician considering AOD-9604 for a patient with obesity who qualifies for a GLP-1 receptor agonist should document the clinical reasoning for choosing the less-studied compound.

What Prescribers and Pharmacies Risk If They Get It Wrong

The FDA's enforcement tools include warning letters, injunctions, and seizure actions against compounding pharmacies found to be using bulk substances not on the affirmative list. The FDA sent warning letters to multiple compounding facilities between 2020 and 2024 related to unapproved peptides [10]. A Virginia physician who prescribes a peptide compound without documented clinical rationale risks Board of Medicine disciplinary action, including license suspension.

Patients who purchase AOD-9604 from sources that are not licensed Virginia compounding pharmacies, including international online vendors or domestic websites operating without pharmacy licensure, have no legal protection and no quality assurance. The FDA's analysis of imported compounded products has documented contamination and significant potency deviations [10].